Avanos Medical today announced it entered into a definitive agreement to acquire OrthogenRx for $160 million.
OrthogenRx makes viscosupplementation therapies to treat knee osteoarthritis pain, as well as commercial hyaluronic acid (HA) therapy products GenVisc 850 and TriVisc. Avanos will purchase the company for $130 million in cash at closing and an additional $30 million in contingent cash consideration upon the achievement of growth milestones related to the HA therapy products.
Get the full story on our sister site, Drug Delivery Business News.